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CXCR3 plays important roles in angiogenesis, inﬂammation, and cancer. However, the precise
mechanism of regulation and activity in tumors is not well known. We focused on CXCR3-A
conformation and on the mechanisms controlling its activity and trafﬁcking and investigated
the role of CXCR3/LRP1 cross talk in tumor cell invasion. Here we report that agonist
stimulation induces an anisotropic response with conformational changes of CXCR3-A along
its longitudinal axis. CXCR3-A is internalized via clathrin-coated vesicles and recycled by
retrograde trafﬁcking. We demonstrate that CXCR3-A interacts with LRP1. Silencing of LRP1
leads to an increase in the magnitude of ligand-induced conformational change with CXCR3-
A focalized at the cell membrane, leading to a sustained receptor activity and an increase in
tumor cell migration. This was validated in patient-derived glioma cells and patient samples.
Our study deﬁnes LRP1 as a regulator of CXCR3, which may have important consequences for
tumor biology.
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The CXC chemokine receptor CXCR3 belongs to the familyof G-protein-coupled receptors (GPCRs) that mediatediverse biological functions upon extracellular stimuli.
CXCR3 has been reported to interact with various CXC chemo-
kines (CXCL9-11, CXCL4, and CXCL4L1). Increase in CXCR3
expression has been found in many human tumors and has been
correlated with poor prognosis in patients with breast cancer,
colon cancer, glioma and osteosarcoma1–4.
Three distinct CXCR3 spliced isoforms have been described
including CXCR3-A, CXCR3-B, and CXCR3-alt, CXCR3-A and
CXCR3-B being the most important. CXCR3-B displays a longer
amino-terminal domain than CXCR3-A5. CXCR3-A is reported
to promote cell proliferation, survival and migration, while
CXCR3-B mediates growth inhibitory activity and apoptosis6–9.
In renal carcinoma cells, the relative expression of CXCR3-A and
CXCR3-B determines the effect on cell proliferation and survival
and overexpression of CXCR3-B signiﬁcantly inhibits cell pro-
liferation and promotes apoptosis6. In gastric cancers, over-
expresssion of CXCR3-B correlates with favorable prognosis10.
Thus, CXCR3-A appears to mediate "switch on" signaling while
CXCR3-B appears to mediate "switch off" signaling in tumors.
CXCR3 increases intracellular calcium levels and activates
multiple signaling pathways, related to actin reorganization,
proliferation, chemotactic migration, invasion, and cell survival.
Many reports have shown that in various cell types (pericytes,
endothelial cells, myoﬁbroblast, T cells, epithelial cells, and tumor
cells), binding of CXC chemokines to CXCR3 induces activation
of p38 and ERK/mitogen activated protein kinases (MAPK),
phosphatidylinositol 3-kinase (PI3K), and phospholipase C (PLC)
11–14.
Plasmon waveguide resonance (PWR) has been demonstrated
ideal to follow GPCR activation and ﬁrst signaling events15, 16.
This method is highly sensitive and allows direct assessment of
binding afﬁnity and kinetics. Additionally, it can follow the
orientation of anisotropic-oriented samples.
Lipoprotein receptor-related protein-1 (LRP1) is a large multi-
ligand endocytic receptor that belongs to the low-density lipo-
protein receptor family17. Members of this family were thought to
be exclusively involved in receptor-mediated uptake of extra-
cellular molecules, but many studies have revealed new roles of
this family of receptors. LRP1 is widely expressed in several cell
types including ﬁbroblasts, neurons, astrocytes, macrophages,
smooth muscle cells, and tumor cells. LRP1 is synthesized as a
600-kDa precursor protein that interacts with the ER chaperone
receptor-associated protein (RAP)18 and is processed into an
extracellular ligand-binding subunit of 515 KDa (α chain) and a
transmembrane (TM) and intracellular subunit of 85-kDa
(β chain). The α-chain contains four extracellular ligand-
binding domains (I–IV), and the intracellular domain of the β
chain binds several adaptor proteins for efﬁcient endocytic traf-
ﬁcking and signaling19. LRP1 is reported to regulate the abun-
dance or the function of receptors/cell signaling proteins in the
plasma membrane, including uPAR, EphA2, and neuropilin-120–
23. LRP1 has been reported to mediate endothelial and mega-
karyocyte cells responses to the CXC chemokine CXCL424, 25.
Mice lacking LRP1 in smooth muscle cells show greatly dimin-
ished vessel integrity26. Nakajima et al.23 further demonstrated
that LRP1 modulates the GPCR sphingosine-1-phosphate (S1P)
signaling but does not interact with GPCR S1P. LRP1 is also
critically involved in many processes that drive tumorigenesis and
tumor progression27.
In this article, we studied the status of CXCR3-A in tumor cells
and new observations for receptor conformation, function, and
regulation are presented. Furthermore, PWR provided new
insights into CXCR3 activation at a structural level. One of our
main ﬁnding is the involvement of LRP1 in the regulation of
CXCR3 bioactivity and trafﬁcking. This has signiﬁcance for
tumor inﬁltration at a fundamental and clinical level. This study
reports an interaction between a classical CXC chemokine
receptor and LRP1, and shows a regulatory role of LRP1 in GPCR
conformation, trafﬁcking, and biological activity in tumor cells.
Results
Expression and function of CXCR3 in glioma cells. We inves-
tigated the expression of CXCR3 isoforms in different glioma cell
lines (Supplementary Fig. 1A) by quantitative real-time PCR to
distinguish CXCR3-A from CXCR3-B. Glioma cell lines express
both CXCR3-A and CXCR3-B messenger RNA (mRNA)
(Fig. 1a). Endogenous CXCR3 protein levels measured in all
glioma cell lines by immunoblotting were variable (Fig. 1b). We
used the U87 glioma cell line in the subsequent studies since it
expresses low CXCR3 levels (Fig. 1b) and can, therefore, be
engineered with adequate expression vectors. To reinforce our
results, we used, in addition, the HEK-293 cell line which also
expresses low CXCR3 levels (Fig. 1b).
We focused our study on CXCR3-A function and stably
transfected U87 cells with vectors encoding CXCR3-A (U87-
CXCR3-A). CXCR3-A expression was validated in transfected cell
lines (Supplementary Fig. 1). U87-CXCR3-A cells migrated more
(ﬁve-fold increase) in response to the CXCR3 agonist (PS372424)
in comparison to empty-vector transfected control cells (U87-
CTRL) (Fig. 1c). The increase in cell migration was inhibited by
the treatment using a CXCR3 antagonist (SCH546738) (Fig. 1c).
To reinforce the results, we used the T98G cell line that expresses
endogenously signiﬁcant levels of CXCR3-A compared to U87
(Fig. 1a). CXCR3 silencing in these cells inhibited migration
(Supplementary Fig. 2A).
To study tumor growth and metastasis in vivo, the chick
embryo’s chorioallantoic membrane (CAM) model was
implanted with U87-CTRL and U87-CXCR3-A cells (Fig. 1d).
U87-CXCR3-A tumors expressed high amounts of CXCR3-A
in vivo compared to U87-CTRL tumors (Fig. 1d, e). U87-CXCR3-
A tumors displayed invasion with tumor strands invading the
chicken host tissue, in contrast to U87-CTRL, which were
circumscribed and highly angiogenic (Fig. 1d). Accordingly, uPA
and metalloproteinases expression levels were increased in U87-
CXCR3-A tumors (Fig. 1e). Blockade of CXCR3-A by
SCH546738 leads to a strong inhibition of tumor invasion in
the CAM model (Supplementary Fig. 2B).
Conformational and dynamic properties of CXCR3-A. We next
conducted PWR experiments. This technique is able to determine
binding afﬁnity and kinetics. Additionally, it can probe changes in
the molecular orientation of anisotropic lipid membranes and
their embedded proteins by the use of two polarizations, per-
pendicular (p-pol) and parallel (s-pol) to the sensor surface. These
correspond, respectively, to the long and short axis of lipids and
proteins (Fig. 2a)28, 29. PWR is a well-established method to
follow ligand-induced receptor conformational changes15, 16, 30,
31. Herein, we have detached membrane fragments from cells in
culture (for details see Methods section). Membrane fragments of
U87-CTRL or U87-CXCR3-A cells immobilized onto silica (glass
slides or PWR sensor) pretreated with polylysine were analyzed
by ﬂuorescence microscopy and PWR. U87 cell membrane
fragments were adsorbed on the slide and cell fragments rather
than whole cells containing the CXCR3-A were indeed captured
by this method (Supplementary Fig. 3A). PWR spectra performed
before and after cell adhesion on the sensor showed a large
increase in resonance minimum position (about 100 mdeg) that
can be explained by mass increase due to the capture of cell
fragments (Fig. 2b). The magnitude of the spectral shift correlated
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Fig. 1 Expression and functional role of CXCR3-A in glioma. a Relative CXCR3 isoform mRNA expression in low (1321N1, NHATS, and NHATSR) and high-
grade (U87, U118, and T98G) glioma. Values normalized to those obtained for U87 cell line. b CXCR3 protein expression in HEK-293 and glioma cell lines.
Vinculin was used as a loading control. cMigration assays using CXCR3 agonist PS372424 (100 ng/ml) were performed in U87-CTRL and U87-CXCR3-A
cells. U87-CXCR3-A cells were pretreated or not with CXCR3 antagonist SCH546738. NS non-stimulated condition, DMSO negative control. d CAM
assays were performed using U87-CTRL (n= 21 eggs) or U87-CXCR3-A cells (n= 23 eggs). Seven days after implantation, images of CAM tumors with
CXCR3 immunostaining and HE staining with corresponding vimentin immunostaining were performed in U87-CTRL and U87-CXCR3-A. e Relative
CXCR3-A, MMP-2, or uPA mRNA expression in U87-CTRL and U87-CXCR3-A tumors (n= 7 eggs for each condition). All the results from three
independent experiments were combined to calculate mean and SEM, and values were normalized to those obtained for the control cells. ***P<0.001,
**P<0.01, *P<0.05. Multiple comparisons were performed with one-way analysis of variance, followed by Bonferroni post hoc tests. Statistical comparison
between two groups was performed using the Mann–Whitney U-test
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Fig. 2 Conformational dynamic properties and activation of CXCR3-A. a Schematic representation of the p-polarized light perpendicular to CXCR3 (referred
as P-Pol for elongation of the receptor in the plasma membrane) and of the s-polarized light parallel to CXCR3 (referred as S-Pol for spreading of the
receptor along the plasma membrane). b PWR spectra for the PWR sensor before and after immobilization of the cell fragments obtained with p-(left
panel) and s-(right panel) polarized light in U87-CXCR3-A cells. c Changes in the minimum resonance position following incremental addition of CXCR3
agonist PS372424 to U87-CXCR3-A cell fragments as a function of time obtained with p-(left panel) and s-(right panel) polarized lights. d Binding curve
and KD values for PS372424 interaction with CXCR3-A in HEK-CXCR3-A and U87-CXCR3-A. e Relative calcium-induced ﬂux in HEK-CTRL/HEK-CXCR3-A
cells (left panel) and in U87-CTRL/U87-CXCR3-A cells (right panel) after 20 s of CXCR3 agonist PS372424 stimulation. f Relative calcium ﬂux in
non-stimulated (NS) and stimulated HEK-CXCR3-A cells (left panel) and U87-CXCR3-A cells (right panel) when cells were pretreated or not with CXCR3
antagonist SCH546738. DMSO negative control, a.u. arbitrary unit. ***P<0.001, **P<0.01, *P<0.05. g CXCR3 activation assessed by measuring the
phosphorylation level of ERK1/2 after 5 min of stimulation (100 ng/ml of CXCR3 agonists: PS372424, CXCL10, or CXCL4L1). h Activation of MAPK/ERK
pathways after CXCR3 stimulation when cells were pretreated or not with CXCR3 antagonist SCH546738. Total ERK was used as loading control. All the
results represent three independent experiments combined to calculate mean and SEM. Values were normalized to those obtained for the control cells.
Multiple comparisons were performed with one-way analysis of variance, followed by Bonferroni post hoc tests
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well with that observed for a pure lipid membrane across the
entire PWR sensor29 and our results are comparable to the ani-
sotropic response found for other GPCRs31, although the
deposition method was different. The addition of the agonist
PS372424 to the U87-CXCR3-A cell fragments captured on the
sensor led to spectral changes for both polarizations, but espe-
cially for the p-polarization (Fig. 2c) and no spectral changes were
observed with U87-CTRL cell fragments. This reﬂects con-
formational changes of CXCR3-A along the receptor longitudinal
axis (elongation) and indicate that ligand binding is speciﬁc.
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Moreover, binding of PS372424 to U87-CXCR3-A membranes
was saturable (KD of 36± 9 nM) (Fig. 2d). Similar receptor con-
formational changes and afﬁnity were obtained with HEK-293
cells transfected with vectors encoding for CXCR3-A (HEK-
CXCR3-A) (Fig. 2d; Supplementary Figs. 1, 3).
PS372424 is a three amino-acid fragment of CXCL10. Similar
results were obtained by using full-length CXCL10 albeit the
binding afﬁnity was higher (see Supplementary Fig. 6A later in
the article).
Downstream activation of CXCR3-A in glioma cells. GPCRs are
critically regulated by β-arrestins, which not only desensitize G-
protein signaling but also initiate a G-protein-independent wave
of signaling pathways. Our results show that after 15 min of sti-
mulation, β-arrestin 1, and β-arrestin 2 are localized at the cell
membrane (Supplementary Fig. 4A). Stimulation with PS372424
led to a peak in intracellular calcium levels after 20 s only in cells
expressing CXCR3-A and is inhibited by SCH546738 (Fig. 2e, f).
PS372424, CXCL10, and CXCL4L1 increased phospho-Erk1 and
phospho-Erk2 in U87-CXCR3-A cells after 5 min of stimulation
and this was inhibited by SCH546738 (Fig. 2g, h; Supplementary
Fig. 3F, G).
First evidence for an interaction between CXCR3 and LRP1.
We next investigated a possible link between CXCR3 and LRP1.
We demonstrated by stimulated emission depletion (STED)
microscopy that both CXCR3-A and LRP1 were present in the
cytoplasm near the nucleus and at the membrane, and colocalized
perfectly in the super resolution space (100 nm) of the STED
(Fig. 3a, left panel; Supplementary Fig. 4B). We showed that in
basal condition 55% of LRP1 colocalized with CXCR3-A and 30%
of CXCR3 with LRP1 (Fig. 3a, right panels). This does not take
into account juxta-positioned CXCR3 and LRP1 in which case the
values would be higher. Double staining with antibodies against
CXCR3 and LRP1 conﬁrmed colocalization of LRP1 with
CXCR3-A especially at the perinuclear area in basal condition
(Pearson’s correlation> 0.5) (Supplementary Fig. 4C). Upon sti-
mulation with PS372424, both receptors were localized at the cell
membrane, and Pearson’s correlation was increased (Supple-
mentary Fig. 4C). Furthermore, CXCR3 and LRP1 were co-
immunoprecipitated in U87-CXCR3-A cells (Fig. 3b).
To validate this interaction in cell expressing endogenous
receptors, we used the glioma cell line 1321N1 (Fig. 1b) and the
coronary artery smooth muscle cells (CaSMC)26. In all cases, both
LRP1 subunits and CXCR3 could be co-immunoprecipitated
(Fig. 3b). The CXCR3 and LRP1 interaction was also evidenced
in vivo in U87-CXCR3-A CAM tumors and in patient-derived
glioblastoma cells (Fig. 3c, d). In comparison, CXCR7 known to
be involved in glioma development32, is expressed in U87 cells
but was unable to interact with LRP1 (Fig. 3e).
To reinforce these results, we performed proximity ligation
assay (PLA) experiments. U87-CXCR3-A cells were incubated
with speciﬁc antibodies that recognize CXCR3 and LRP1. These
experiments clearly show that CXCR3 and LRP1 colocalize
(Fig. 3f). Appropriate controls were done which ascertained the
speciﬁcity of the results.
CXCR3-A binds LRP1 through its ligand-binding domain IV.
RAP known to antagonize ligand binding to LRP1 (domains I, II,
and IV)33 was able to signiﬁcantly reduce CXCR3:LRP1 complex
formation (Fig. 4a). This indicates that CXCR3-A interacts with
the α chain of LRP1. HEK-CXCR3-A cells that only express low
level of LRP1 were stably transfected with an HA-tagged mini-
receptor derived from full-length LRP1 carrying only the ligand-
binding domain IV (HA-LRPIV) (Fig. 4b). The CXCR3:LRP1
complex could also be immunoprecipitated in this case (Fig. 4b).
These data demonstrate that LRP1 domain IV (LRPIV) is criti-
cally involved in CXCR3-A binding. To reinforce our data, we
modeled the interaction between CXCR3- and the cystein-rich
complement-type repeats (CR) of the LRPIV. The LRPIV con-
tains CR 21-31. CR26 and CR27 have positive charged residues
that may interact with the open ligand-binding pocket of GPCR,
which contains many negatively charged residues34, 35. Separate
molecular docking was performed between CXCR3-A and CR26
and CR27, respectively, using HADDOCK2.236, 37. Only the
HADDOCK output for the CXCR3-A:CR26 complex gave ﬁve
clusters, while CR27 showed a less deﬁned orientation for
CXCR3-A binding. Positively charged residues within the CR26
N-terminus formed a continuously positive patch for the binding
of CXCR3-A extracellular region. There are three basic residues
(Arg, Lys, and Arg at position 3542, 3544, and 3547) found in the
CR26 ﬁrst and second β-sheets. A representative model is shown
in Fig. 4c. The β1-loop-β2 was docked into CXCR3-A negatively
charged pocket. The extracellular loop 2 (ECL2) in CXCR3-A has
proper orientation for the interaction with the CR26 β1-loop-β2.
Residues E196 and D195 in ECL2 are close to CR26 β1-loop-β2.
This allows substantial attractive charge-based interactions.
Next, we modeled the interaction in the presence of the agonist
PS372424 or full-length CXCL10 (Fig. 4d, e). Based on the model,
CR26 engages CXCR3 mainly through the interaction with ECL2.
In presence of PS372424, CR26 binding to CXCR3 is not
overlapping with agonist binding to CXCR3, since PS372424
occupies only the inside of the GPCR hydrophobic pocket.
Furthermore, CR26 is unable to penetrate deep into the binding
pocket to interfere with agonist binding to CXCR3. Comparing
the binding mode with that of the agonist, CXCL10 also displays
a deep penetration into CXCR3 hydrophobic pocket. Further-
more, CXCL10 has a much wider binding surface and possesses
more interactions with CXCR3, including an interaction with the
receptor’s N-terminus and the hydrophobic pocket. Therefore, we
expect higher afﬁnity of the full-length chemokine for CXCR3.
This is indeed the case as our PWR results demonstrate (KD of
2.9± 0.8 nM for CXCL10 vs. KD of 36± 9 nM for PS372424;
Supplementary Fig. 6 below).
Fig. 3 Interaction of CXCR3 with LRP1. a Super resolution microscopy (STED) for U87-CXCR3-A cells (CXCR3 λ= 594 nm, LRP1 λ= 647 nm). Zoom 1
represents the perinuclear area in the cell and zoom 2 the membrane area of the cell. Scale: 5 and 1 µm (zoom). ×1000 magniﬁcation under a Leica
SP8-STED microscope. The graph depicts the percentage of colocalization of each ﬂuorophore with CXCR3 or LRP1 (n= 30). ***P<0.001. Statistical
comparison between two groups was performed using the Mann–Whitney U-test. b Immunoprecipitation against LRP1 (IP LRP1α, antibody LRP1 8G1 for
glioma cells, and antibody LRP1 D2642 for CaSMC) and western blot of the CXCR3:LRP1 complex (antibody 8G1 for LRP1α and 5A6 and 2703-1 for LRP1β)
in glioma cells and coronary artery smooth muscle cells (CaSMC). CTRL IgG negative control of beads with IgG. c, d Immunoprecipitation against LRP1 (IP
LRP1α, antibody LRP1 8G1) and western blot of the CXCR3:LRP1 complex (antibody 8G1 for LRP1α) in U87-CTRL and U87-CXCR3-A tumors implanted in
the CAM (c) and in several GBM cell lines derived from patients (d). eWestern blot probed with anti-CXCR7 and anti-CXCR3 antibodies in U87-CXCR3-A
and immunoprecipitation against LRP1 (IP LRP1α, antibody LRP1 8G1). The experiments have been repeated three times with identical results. f Proximity
ligation assay (PLA) in U87-CXCR3-A cells between CXCR3 and LRP1 using anti-CXCR3 (mouse 2 ar1) and anti-LRP1 antibodies (2703-1, rabbit
monoclonal antibody for LRP1β)
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Clathrin-dependent internalization and recycling. We next
aimed at studying CXCR3 trafﬁcking because LRP1 is an endo-
cytic receptor. To investigate clathrin-dependent and indepen-
dent pathways, we performed studies using antibodies for
clathrin, for early endosomes (EEA1 and Rab5), for trans-Golgi
recycling network (GOPC and syntaxin 6) or for lysosomal
degradation pathway (Lamp-1). In unstimulated U87-CXCR3-A
cells, colocalization of CXCR3-A with each marker was found
near to the nucleus (Fig. 5a). In agonist-stimulated U87-CXCR3-
A cells, colocalization was also seen at the plasma membrane for
all markers, and the Pearson’s correlation was increased for cla-
thrin and EEA1 after 15 min of stimulation (Fig. 5a;
Supplementary Fig. 4D). At 60 min of stimulation, CXCR3-A,
LRP1, GOPC, and syntaxin 6 were mainly detected in the cyto-
plasm (Fig. 5a). CXCR3-A colocalized with GOPC and syntaxin
6, suggesting its recycling through the trans-Golgi network. The
same results were obtained in the HEK-CXCR3-A cells with
clathrin, EEA1, and Rab5 immunostaining at 15 min of agonist
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stimulation and with GOPC and syntaxin 6 immunostaining at
60 min of stimulation (Supplementary Fig. 5A). Immunogold
labeling of ultrathin cryosections of U87-CXCR3-A cells
demonstrated that CXCR3 and syntaxin 6 are both present in the
trans-golgi network. These results conﬁrm the localization of
CXCR3 in the recycling compartment (Fig. 5b).
Furthermore, silencing of clathrin (Fig. 6a, b) demonstrated
that CXCR3-A remained at the cell membrane under unstimu-
lated conditions and after 60 min of stimulation (Fig. 6c–f). This
was conﬁrmed by inhibition of clathrin by Pitstop2, even if this
inhibitor has some non-speciﬁc effects38. After 3 min of
stimulation, a sustained increase in intracellular calcium was
observed (Fig. 6g). We demonstrated that CXCR3-A is inter-
nalized with LRP1 in a clathrin-dependent manner to EEA1-
positive early endosomes. No colocalization was found with
caveolin and late endosomes or lysosomes (Supplementary
Fig. 5B), which indicated that endocytosed CXCR3 receptors
were protected from lysosomal degradation. This indicates that
CXCR3 and LRP1 use a recycling pathway leading to a slower
receptor turnover.
LRP1 as a regulator of CXCR3 activity and function. We stu-
died whether LRP1 is involved in CXCR3-A conformational
dynamics and trafﬁcking. Silencing of LRP1 expression was
performed in U87-CTRL and U87-CXCR3-A cells using three
interference RNAs against human LRP1 with strong and similar
efﬁciency (90% of LRP1 silencing) (Fig. 7a). In small interfering
RNA (siRNA) LRP1-treated cells and stimulated with PS372424,
both the magnitude (spectral shifts reported in mdeg) and the
anisotropy of the response (ratio of the spectral shifts observed
with the p- ad s-pol light) are altered (Fig. 7b; Supplementary
Fig. 3D). The magnitude of the spectral changes induced by the
ligand in siRNA LRP1 U87-CXCR3-A-treated cells was more
than two-fold (45 and 25 mdeg for p- and s-polarization,
respectively) when compared to cells treated with control siRNA
(19 and 6 mdeg for p- and s-polarization, respectively) (Fig. 7b).
This is correlated with a higher amount of receptors present in
the cell fragments (Fig. 7c). Thus, the data support the idea that
LRP1 depletion leads to receptor accumulation at the cell mem-
brane and a ligand-induced conformational change. Also, the
anisotropy of the ligand-induced receptor conformational change
was greatly altered in siRNA LRP1-treated cells (Fig. 7b). This
indicates that ligand-induced conformational change of the
receptor is affected by the presence of LRP1 in the membrane.
However, ligand afﬁnity for the receptor is very much comparable
to that observed in U87-CXCR3-A treated with control siRNA
(KD of 38± 9 for siRNA LRP1 and KD of 41± 11 for siRNA
control) (Supplementary Fig. 3E).
When using the full-length CXCL10 in these experiments, the
afﬁnity of the ligand was also not altered after LRP1 depletion
(2.9± 0.8 nM siRNA Control vs. 3.2± 0.7 nM siRNA LRP1)
(Supplementary Fig. 6A). P-pol and s-pol values were strikingly
modiﬁed and increased of about 60–50% for s-pol and p-pol,
respectively, after LRP1 depletion (Supplementary Fig. 6A).
Flow cytometry and western blot for CXCR3 on subcellular
membranous fractionation conﬁrmed the increase of CXCR3-A
at the cell membrane when LRP1 is depleted (Fig. 7d, f).
Furthermore, modiﬁcations in the subcellular localization of
CXCR3 were observed when LRP1 was depleted. LRP1 silencing
showed that CXCR3-A accumulated at the cell membrane from
the rear to the front and along membrane rufﬂes (Fig. 7e;
Supplementary Fig. 6B). Clathrin was still recruited and
colocalized with CXCR3-A at the plasma membrane in the
absence of LRP1 (Fig. 7g). This indicates that internalization of
CXCR3-A is strongly inhibited in the absence of LRP1 and
associated with impaired clathrin-coated vesicle formation
(Fig. 7g).
In U87-CXCR3-A cells silenced for LRP1, we observed that the
increase in intracellular calcium level was not only present 20 s
after stimulation with the CXCR3 agonist but was sustained for a
prolonged period of time (up to 3 min, Fig. 8a). The same
experiments were performed in the glioma cell line T98G that
expresses endogenously signiﬁcant levels of CXCR3-A compared
to U87 cells (Fig. 1a). CXCR3-A activation was observed 20 s after
stimulation and sustained 1 min post stimulation when LRP1 was
silenced (Fig. 8b). In addition, a marked phosphorylation of Erk1/
2 was still observed in U87-CXCR3-A cells at 60 min of
stimulation when LRP1 was depleted (Fig. 8c, left panel). The
same results were obtained using RAP, known to competitively
inhibit LRP1-dependent endocytosis (Fig. 8c, right panel). Finally,
cell migration was increased in agonist-stimulated U87-CXCR3-
A cells after LRP1 depletion (Fig. 8d, left panel) or LRP1
inhibition using RAP (Fig. 8d, right panel). Since the inhibition of
LRP1 leads to cell invasion, we further studied the expression of
LRP1 in U87-CTRL and U87-CXCR3-A CAM tumors.
Co-immunostainings for vimentin (to label human U87 cells)
and for LRP1 demonstrated that LRP1 expression was strongly
downregulated in the invasive part of U87-CXCR3-A CAM
tumors (Fig. 8e).
LRP1 and CXCR3 expression in glioma samples from patients.
CXCR3 and LRP1 are expressed in low- and high-grade
gliomas39. Data from global data base-derived analyses do not
take into account the regional heterogeneity of gliomas. We
therefore analyzed the regional distribution of CXCR3 and LRP1
by focusing on high-grade gliomas (glioblastomas, GBM). To this
aim, biopsy spheroids of the human P3 GBM were implanted into
the brain of immunodeﬁcient mice to assess in vivo the expres-
sion of LRP1 and CXCR3. This experimental mouse intracranial
GBM model recapitulates the regional heterogeneity of gliomas
(Fig. 9a)40. Vimentin staining was performed to localize human
P3 GBM cells in the mouse brain. We demonstrated that LRP1 is
strongly expressed in the angiogenic part of the tumor, while it is
decreased in the invasive part of the tumor (Fig. 9b, c). Regarding
CXCR3 expression, reliable antibodies are lacking as they are
produced in the mouse and cross-react with mouse tissue in the
xenograft mouse model. Additionally, patients samples were
taken from central and peripheral areas of the tumor based on
intraoperative neuronavigated MR imaging sample collection
(Fig. 9d). In the angiogenic core of the tumors, CXCR3 and LRP1
were both detected (Fig. 9e). LRP1 was localized in tumor,
stroma, and vascular cells, whereas CXCR3 was only detected in
tumor cells and localized in the cytoplasm (Fig. 9e). In the
invasive part of the tumor, LRP1 expression was completely shut
down while CXCR3 was still present in tumor cells. Most
importantly, CXCR3 was localized at the cell membrane in this
case (Fig. 9e). These results are in agreement with our mechan-
istic studies where we modulated the expression of LRP1 and
CXCR3 in glioma cells. Taken together, our results are in favor of
a role of CXCR3 and LRP1 in tumor cell invasion and inﬁltration,
where LRP1 is downregulated at the invasive areas to allow
accumulation of CXCR3 at the cell membrane leading to a sus-
tained CXCR3 activation and increased tumor cell invasion.
Discussion
Several studies have reported a role of CXCR3 in tumor growth
and metastasis1–3, 9. However, the presence of three distinct
spliced isoforms leads to functional diversity of CXCR3s.
In this article, we focused on the CXCR3-A isoform using
glioma cells as a model system. Gliomas are classiﬁed according
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to World Health Organization (WHO)41 from low- to high-grade
gliomas. Grade IV tumors (glioblastoma multiforme, GBM) are
highly malignant and usually resistant to chemotherapy. Glio-
blastomas are highly vascularized, proliferative, inﬁltrative, and
associated with a poor prognosis42. Recent reports suggest an
involvement of CXCR3 in glioma development4, 43. A strong
correlation of CXCL10/CXCR3 expression with tumor grade in
cultured cells derived from grade III astrocytomas and from grade
IV glioblastomas has been reported44. However, neither the
speciﬁc roles of the CXCR3 isoforms nor the mechanisms of
activation and the regional variations of expression within the
tumor have been investigated in these studies.
We found that CXCR3 isoforms mRNAs were expressed at
variable levels in glioma cell lines of various grade as previously
published43. It was also reported that high expression levels of
CXCR3 conferred poor prognosis and could represent an inde-
pendent prognostic marker for glioblastomas4. This is in contrast
to TGCA and Sun et al.39 data, where global expression CXCR3
does not impact on survival in GBM.
The functional role of CXCR3-A was studied in U87 glioma
cells overexpressing CXCR3-A, in glioma cells that endogenously
express high levels of CXCR3 and in cells from glioblastoma
patients. In vitro cell migration experiments and analysis in the
chick embryo glioma model demonstrated that CXCR3-A
increases cell glioma migration and invasion. CXCR3-A over-
expressing tumors exhibited reduced angiogenesis but increased
invasiveness with tumor strands migrating away from the main
tumor mass in vicinity of CAM blood vessels. These results
clearly show that CXCR3-A promotes glioma cell migration,
which is consistent with a pro-invasive effect and is in agreement
with the clinical data.
We used PWR to study the conformational dynamics and
activity of CXCR3-A. The PWR results demonstrated that ligand-
induced spectral changes lead to mass increases. In as much as
the ligand by itself cannot explain such larger spectral changes,
those correspond to receptor conformational changes with an
overall increase in membrane mass density. Additionally, ligand-
induced spectral changes were anisotropic. This reﬂects aniso-
tropic conformational changes in the receptor with larger changes
along the receptor longitudinal axis explained by receptor elon-
gation. It is noteworthy that the conformational change observed
here did not modify the afﬁnity for the ligand. This implies that
receptor elongation is not signiﬁcantly affecting ligand afﬁnity.
Plasmon resonance studies on rhodopsin, which, like CXCR3
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belongs to class A of the GPCR family, have demonstrated that
upon light activation, the surrounding lipid environment suffers a
considerable increase in membrane thickness45. This was
conﬁrmed by high-resolution structural studies where protein
elongation was attributed to structural changes along the TM
helix 546, 47.
Stimulation of CXCR3-positive glioma cells with the agonist
led to a marked increase in calcium ﬂux and in phospho-Erk1 and
phospho-Erk2. These results are in agreement with earlier studies
that have shown that CXCR3 is able to elicit an increase in
intracellular calcium level and activation of multiple signaling
pathways11–14, 48. This correlates with the ability of CXCR3 to
induce invasion and cell survival, compatible with a role in
metastasis1, 6.
Receptor internalization limits receptor availability at the cell
surface, and thus ligand binding. When receptors reach endo-
somes, they can be sorted directed into the recycling pathway or
targeting into the degradative pathway. Diverse mechanisms of
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endocytosis have been reported for GPCR49. For CXCR3, most of
the studies have been performed in T lymphocytes. The chemo-
kine system is rather complex in these cells, as ligands of CXCR3
can preferentially activate distinct internalization pathways50.
Meiser et al.51 have described in detail endocytosis of CXCR3 in T
lymphocytes after CXCL11 stimulation. They showed that
CXCR3 is rapidly downregulated and that CXCR3 can be inter-
nalized independently of clathrin, β-arrestin 1/2. CXCR3 is
directed into the degradative pathway, mediated in part by
lysosomes and proteaosome, leading to long-term attenuation of
signaling. Cell surface replenishment of CXCR3 occurred over
several hours and is dependent upon de novo CXCR3 synthesis.
This is in stark contrast with our study. We demonstrated that β-
arrestin 1/2 was localized to the membrane just 15 min after
agonist stimulation. CXCR3-A was rapidly internalized via
clathrin-coated vesicles enriched with LRP1, and then recycled to
the cell surface using retrograde trafﬁcking from endosomes to
the trans-Golgi network. A similar recycling mechanism has
already been described for GPCR β1-adrenergic and GLUT4
receptors52, 53. We can only speculate about the reasons for these
differences. Our study investigates CXCR3 kinetics in tumor cells
and not immune cells. Furthermore, the difference may reside in
the ligands used in both studies. Our contention is supported by
Luker et al.54 who showed that, in breast cancer cells, GPCR
CXCR7 trafﬁcking is regulated by β-arrestin 2 and that inter-
nalization is clathrin-dependent. They further demonstrated that
CXCR7 was recycled to the cell membrane. CXCR7 has properties
similar to those of CXCR3 in that it is known to promote tumor
growth and metastasis in mammary carcinoma and glioma32.
Goodman et al.55 also showed that β-arrestin functions as an
adaptor in the receptor-mediated endocytosis pathway, and
suggest a general mechanism for regulating the trafﬁcking of
GPCRs. Plasma membrane localization and beginning of inter-
nalization of CXCR3-A were observed after short-term stimula-
tion. The mechanisms of relocalization of CXCR3-A to the
membrane after agonist stimulation is at present not known.
Complete internalization with cytoplasmic localization of
CXCR3-A was observed after long-term stimulation.
One of the most important aspects of our study is related to the
involvement of LRP1 in CXCR3 conformation, activity and
trafﬁcking. LRP1 has been reported to be involved in tumor
progression, in part through the modulation of the extracellular
tumor environment24, 27, 56. LRP1 is essential for the integrity of
the vascular wall through its capacity to regulate PDGFRβ-
dependent activation of PI3K26, 57. It is, furthermore, critically
involved in invasion and neovascularization, processes which
drive tumor progression and metastasis27. LRP1 expression was
detected in glioblastoma and to a lesser extent in lower-grade
astrocytomas58, 59. In addition, LRP1 has been shown to mediate
endothelial and megakaryocyte cells responses to the CXC che-
mokine CXCL424, 25 and to modulate the GPCR S1P signaling
without interacting with S1P receptors but by restraining the
activation of Gαi subunit23. In our study, LRP1 was critically
involved in CXCR3 activation and trafﬁcking which is an entirely
new ﬁnding for a classical CXC chemokine receptor. We provide
furthermore strong evidence for a physical interaction between
CXCR3 and LRP1, which may have a broad signiﬁcance. This is
based on the following: (1) high-resolution imaging demonstrate
a close spatial proximity between CXCR3 and LRP1, (2) the
complex is co-immunoprecipitated in CXCR3/LRP1 expressing
cells, (3) the complex is present not only in tumor cells, but also
in non-transformed cells such as smooth muscle cells, which have
an important role in vessel maintenance and integrity, (4) the
interaction between CXCR3 and LRP1 was inhibited by RAP, and
(5) a model could be constructed for the CXCR3-A:LRP1 inter-
action involving in ECL2 of CXCR3 and CR26 of LRPIV.
Since, the interaction between CXCR3 and LRP1 was inhibited
using RAP, CXCR3 should mainly interacts with the α chain of
LRP1, known to bind other ligands as well such as uPA, CD44,
and TIMP-160, 61. We clearly demonstrated that the LRPIV is
sufﬁcient for the interaction between CXCR3-A and LRP1, which
is also supported by the molecular docking analysis.
We also depleted or functionally silenced LRP1 using RAP. In
this case, a considerable increase in the magnitude of the ligand-
induced conformational change of CXCR3 and in receptor
number at the membrane was observed. Moreover, the ratio of
the spectral shifts obtained with p- and s-polarization (correlated
with receptor anisotropy) was modiﬁed when LRP1 was depleted.
LRP1 is known to be largely conﬁned to clathrin-coated pits,
which suggests a role in clathrin-dependent internalization60, 62.
We show that silencing of LRP1 inhibits CXCR3 internalization
with an increase of CXCR3 at the cell membrane and that it is
linked to an impairment in the formation of clathrin-coated
vesicles. Furthermore, depletion of clathrin leads to the same
effects, which shows that CXCR3 internalization is clathrin-
dependent and downstream of LRP1.
This resulted in a sustained increase in calcium ﬂux after
agonist stimulation and Erk1/Erk2 phosphorylation after 60 min
of stimulation. In addition, LRP1 depletion or functional silencing
further increased cell migration of glioma cells.
CXCR3 and LRP1 are expressed in low- and high-grade glio-
mas39. These global data base-derived analyses do not take into
account the regional heterogeneity of gliomas. Glioblastomas are
heterogeneous tumors and are characterized by pronounced
angiogenesis and tumor cell inﬁltration. Global analysis of the
tumor transcriptome cannot evidence regional changes in
expression that reﬂect tumor heterogeneity. We clearly show
regional heterogeneity in glioblastoma when various areas from
the angiogenic core and the invasive zone are analyzed. While
CXCR3 is expressed in both, angiogenic and invasive areas, LRP1
expression is strongly reduced in invasive zones of the tumor.
Most importantly, CXCR3 is localized at the tumor cell mem-
brane in invasive areas, while in angiogenic parts of the tumor
CXCR3 is mostly found at an intracellular location. This is in full
agreement with our in vitro mechanistical studies. The inhibition
of LRP1 expression in invasive tumor areas is an important
Fig. 6 Clathrin-dependant internalization of CXCR3-A. Western blot (a) and immunostaining (b) for clathrin in U87-CXCR3-A cells treated with control
siRNA (Si CTRL) or siRNA against human Clathrin heavy chain (Si Clathrin, smart pool of four siRNA, Dharmacon). Tubulin used as a loading control in the
western blot. Scale: 50 µm. a.u. arbitrary unit. ***P<0.001. c Membrane or perinuclear localization of CXCR3 (λ= 547 nm) with Si CTRL or Si Clathrin.
Scale: 5 µm. d FACS analysis of the percentage of CXCR3 at the membrane on U87-CXCR3-A cells treated with Si CTRL or Si Clathrin. ***P<0.001. e
Clathrin-dependent internalization of CXCR3-A. Cells were preincubated with the clathrin inhibitor Pitstop 2tm. Analysis by immunoﬂuorescence at ×630
magniﬁcation under confocal laser scanning microscope (Nikon eclipse Ti). Scale: 5 µm. f Constitutive internalization of CXCR3-A shown by FACS analysis
in HEK-CTRL/HEK-CXCR3-A (left panel) and in U87-CTRL/U87-CXCR3-A (right panel) cells. g Cells were preincubated with the Pitstop 2tm and relative
calcium ﬂux assessed in U87-CTRL and in U87-CXCR3-A cells. NS non-stimulated condition, DMSO negative control, 20 s PS 20 s post stimulation, 3 min
PS 3min post stimulation, a.u. arbitrary unit, NS non-signiﬁcant, ***P<0.01. All the results represent three independent experiments combined to calculate
mean and SEM. Statistical comparison between two groups was performed using the Mann–Whitney U-test. Multiple comparisons were performed with
one-way analysis of variance, followed by Bonferroni post hoc tests
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ﬁnding. It may be of more general signiﬁcance for tumor biology
and may apply to other receptor systems with which LRP1
cooperates and other tumor types as well. These issues as well as
the precise mechanism of silencing will be investigated in follow-
up studies from our laboratory.
Taken together, we provide a number of solid arguments for a
regulatory role of LRP1 in CXCR3 function. Our ﬁndings may
also be of importance for glioma pathobiology (Fig. 10). Indeed,
glioblastoma has a highly invasive behavior and high recurrence
rate because of cells inﬁltrating the adjacent tissues during the
evolution of the disease41. Thus, our ﬁnding may not only enrich
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our knowledge of chemokine biology but also suggest strategy for
therapeutic intervention.
Methods
Reagents and antibodies. CXCR3 agonist (PS372424, ref: 239823) and recom-
binant human CXCL10 (ref: 300-12) were purchased from Calbiochem and
Peprotech, respectively. CXCR3 antagonist (SCH546738) was synthesized and
purchased from ChemExpress (Shanghai, CN). RAP generated as previously
described60. Clathrin inhibitor Pitstop2, mouse monoclonal antibody against
CXCR3 [2ar1] (ref: ab64714), mouse monoclonal antibody against CXCR3 [1C6]
(ref: ab125255), rabbit polyclonal antibody against CXCR3 (ref: ab77907), rabbit
monoclonal antibody against CXCR3 (ref: ab154845), rabbit monoclonal antibody
against CXCR4 (ref: ab124824), rabbit polyclonal antibody against CXCR7 (ref:
ab72100), mouse monoclonal antibody against LRP1 (5a6, epitope in the beta chain
of LRP1) (ref: ab28320), and mouse monoclonal antibody against LRP1 (8G1,
epitope in the alpha chain of LRP1) (ref: ab20384) were purchased from Abcam.
Rabbit monoclonal antibody against LRP1 (ref: 2703-1, epitope in the beta chain of
LRP1) was purchased from Epitomics and goat polyclonal antibody against LRP1
(ref: D2642, epitope in the alpha chain of LRP1) was a kind gift of Pr. Dudley
Strickland (University of Maryland, Baltimore, USA). Mouse monoclonal antibody
against GFP [B-2] (ref: sc-9996) was purchased from Santa Cruz Biotechnology.
Puriﬁed Mouse Anti-β-Arrestin Clone 10/β-Arrestin1 (RUO) was purchased from
BD Bioscience (ref: 610550). Vesicle Trafﬁcking Antibody Sampler Kit (ref: 9765),
Endosomal Marker Antibody Sampler Kit (ref: 12666), PathScan Multiplex western
Cocktail I (ref: 5301S), and rabbit primary antibody against total p42/p44 MAPK
(ref: 9102) were purchased from Cell Signaling Technology. Mouse monoclonal
antibody against vinculin (ref: V9131) was purchased from Sigma-Aldrich. Mouse
monoclonal antibody against human vimentin (ref: sc-6260 clone V9) was pur-
chased from Santa Cruz.
Migration assays. Migration assays were performed on transparent polyethylene
terephthalate (PET) membrane 8.0 µm pore size (ref: 353097, Dutscher). About
25,000 cells were seeded on the top part of the membrane and CXCR3 agonist (100
ng/ml) was added below in the well in serum-free medium. For migration
experiments using RAP, cells were stimulated 24 h with RAP (5 µM) and then
seeded in the top part of the membrane with CXCR3 agonist (100 ng/ml) and RAP
(5 µM). For migration experiments using siRNA for LRP1, CXCR3 agonist gradient
was performed with 100 ng/ml on top part of the membrane and 500 ng/ml below
in the well. After 6 h, cells were ﬁxed 10 min with 30% acetic acid and 40%
methanol and then stained 15 min with 40% methanol, 30% acetic acid, and 0.5%
coomassie blue. Cells which migrated through the membrane were then counted
with an inverted epiﬂuorescence microscope (Nikon Eclipse TE200, Obj ×10).
Gene expression analysis. Total RNA was isolated from cells using Trizol reagent
(ref: TR118, Sigma-Aldrich) according to the manufacter’s instruction. About 1 µg
of total RNA was reverse-transcribed into complimentary DNA (cDNA) using the
high-capacity cDNA reverse transcription kit (AbCam 4368814). The resulting
cDNAs were ampliﬁed using speciﬁc primers for the genes of interest. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) and HPRT (hypoxanthine guanine
phosphoribosyl transferase, Fisher Scientiﬁc, Hs99999909_m1) were used as
internal controls. We applied the real-time PCR method using the FG, POWER
SYBR GREEN PCR (Fisher Scientiﬁc, 10658255) for CXCR3-A: forward sequence
CCATGGTCCTTGAGGTGAGTG and reverse sequence AGCTGAAGTTCTC-
CAGGAGGG, for MMP-2: forward sequence ccgtccccatcatcaa and reverse
sequence aggtattgcactgccaactcttt and for uPA: forward sequence cttaactccaa-
cacgcaagggg and reverse sequence agcttgtgccaaactggggatc. Taqman univ PCR
master mix (Fisher 10157154) was used for CXCR3-B: probe sequence (6FAM)
CCCGTTCCCGCCCTCACAGG, forward sequence TGCCAGGCCTTTACA-
CAGC and reverse sequence TCGGCGTCATTTAGCACTTG. Real-time PCR
reactions were performed on a StepOnePlus Real-Time PCR system using StepOne
software V2.3 (Applied Biosystems).
Recombinant CXCL4L1 expression and puriﬁcation. CXCL4L1 was expressed in
Escherichia coli BL21 (DE3) harboring an expression plasmid, pET-43.1a-
CXCL4L1. Cells were cultured in LB media with 100 μg/ml ampicillin at 37 °C and
subsequently induced by 1 mM isopropyl-thio-β-galactopyranoside (IPTG) for 4 h.
Cells were harvested by centrifugation, stored at −20 °C and resuspended in lysis
buffer (50 mM Tris-HCl, pH 7.4, and 100 mM NaCl), followed by sonication. After
centrifugation, the pellet of recombinant CXCL4L1 was resuspended in lysis buffer
containing 0.8% (v/v) Triton X-100 and 0.8% sodium deoxycholate with stirring
for 20 min at room temperature, followed by centrifugation. This process was
repeated three times. The ﬁnal pellet was dissolved in denaturation buffer (6M
guanidinium hydrochloride, 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, and 5 mM β-
mercaptoethanol) and stirred 2 h at room temperature. The denatured CXCL4L1
was dialyzed with refolding buffer (0.9 M guanidinium chloride, 50 mM Tris-HCl,
pH 8.0, 500 mM NaCl, 5 mM freshly added cysteine and methionine) at 4 °C for 6
h. The refolding buffer was replaced by the binding buffer (50 mM Tris-HCl, pH
7.4, and 500 mM NaCl). Precipitate of protein solution was removed by cen-
trifugation. The protein solution containing folded CXCL4L1 was subjected to a
heparin high-performance afﬁnity column (ÄKTA FPLC system, GE Healthcare)
equilibrated with binding buffer. Bound CXCL4L1 was eluted in 1M NaCl and
injected into a Superdex 75 HR 10/300 column (ÄKTA FPLC system) in 50 mM
sodium phosphate buffer, pH 7.4, 150 mM NaCl. The eluted CXCL4L1 was further
puriﬁed by HPLC system (Beckman Coulter Inc.) using a C18 reverse phase col-
umn (Phenomenex Inc.). The puriﬁed CXCL4L1 was lyophilized and kept frozen at
−80 °C.
Construction of CXCR3 expression plasmids. The coding regions of human
CXCR3-A cDNA were cloned in two consecutive steps. Human CXCR3-A cDNA
fragments were ampliﬁed by PCR (forward primer: aaaacggtaccatggtccttg and
reverse primer: aaaaggatcccaagcccgagt) from pEGFPN2-CXCR3-A. The CXCR3-A
amplicons of 1125 bp were subcloned into the pCDNA3.1+ vector (Amersham
Biosciences). Puriﬁed PCR products were digested with BamHI and KpnI restric-
tion enzymes and inserted into the pCDNA3.1+ vector. Sequences of the plasmids
were conﬁrmed by DNA sequencing.
Flow cytometry analysis. Cells were washed three times with phosphate-buffered
saline (PBS), 5% BSA and labeled in suspension with R-phycoerythrin (PE) mouse
anti-human CD183 (ref: 557185BD, BD Pharmingen) or PE Mouse IgG1, Isotype
Control (ref: 555749, BD Pharmingen) for 20 min at 4 °C. Cells were then washed
three times with PBS, 5% BSA and analyzed on an AccuriC6 ﬂow cytometer with
BD AccuriC6 software (BD, San Jose, CA) as recommended to the manufacturer’s
instruction. A minimum of 10,000 events was recorded per sample.
Small interfering RNA knockdown experiments. For inhibition of CXCR3,
Clathrin, and LRP1 expression, cells were transiently transfected with annealed
siRNA. CXCR3, Clathrin, and LRP1-speciﬁc siRNAs were used (ON-TARGETplus
Human CXCR3 (ref: 2833), ON-TARGETplus Human Clathrin heavy chain (smart
pool of 4 siRNA, L-004001-01-0005), and ON-TARGETplus Human LRP1 (ref:
4035) with siRNA number 7 named siLRP1-3, GE Healthcare Europe GmbH,
Dharmacon). A siRNA-random (siRNA CTRL, SR-CL000-005) used as a negative
control. Two others siRNAs against human LRP1 were synthesized by Eurogentec
(Angers, France). The LRP1-speciﬁc sense and antisense RNA oligonucleotides
were as follows: siLRP1-1/sense siRNA, GCAGUUUGCCUGCAGAGAUtt, and
antisense siRNA, AUCUCUGCAGGCA
AACUGCtt and siLRP1-2/sense SiRNA AUGCUGACCCCGCCGUUGCtt and
antisense siRNA GCAACGGCGGGGUCAGCAUtt. Transfection was performed
using lipofectamine RNAimax Kit (Fisher 10601435) in accordance with the
manufacturer’s protocol, with siRNA at a ﬁnal concentration of 20 nM in media
without antibiotics. After transfection, cells were washed with PBS and fresh
complete media was added for 48 h.
Tumor spheroids and cell culture. P3 GBM cells were taken and cultured from a
patient biopsy63. Patient-derived cell lines were cultured as spheroids in neurobasal
Fig. 7 LRP1-dependent conformational dynamics and internalization of CXCR3-A. a LRP1 downregulation in U87-CTRL and U87-CXCR3-A cells. Western
blot for LRP1 in cells treated with three different siRNA against human LRP1. Vinculin as a loading control. b Changes in the minimum resonance position
following incremental addition of PS372424 to the cell fragments of U87-CXCR3-A cells treated with LRP1 SiRNA (Si LRP1-1) or control SiRNA (Si CTRL) as
a function of time (p-polarization and s-polarization light). c Binding curve for PS372424 interaction with the CXCR3-A following Si CTRL (•) and Si LRP1-1
treatment (•) obtained with the p-polarized light (KD values are provided in Supplementary Fig. 2E). d Percentage of CXCR3-A at the cell membrane
assessed by FACS in Si CTRL- or Si LRP1-1-treated cells. e CXCR3 immunostaining in U87-CXCR3-A cells treated with Si CTRL or three different siRNA
against human LRP1. Scale: 5 μm. f The amount of CXCR3-A in cell membrane extracts assessed by western blotting. Caveolin as a membrane loading
control. g CXCR3-A (λ= 488 nm), LRP1 (λ= 547 nm), and clathrin (λ= 647 nm) immunostainings in U87-CXCR3-A cells treated with Si CTRL or Si LRP1-1
upon stimulation (PS372424, 100 ng/ml, 60min). All sections were observed at ×630 magniﬁcation under confocal laser scanning microscope (Nikon
eclipse Ti). Scale: 5 μm. Results from three independent experiments combined to calculate mean and SEM, and values normalized to those obtained for
the control condition. ***P<0.001, **P<0.01, *P<0.05. Multiple comparisons were performed with one-way analysis of variance, followed by Bonferroni
post hoc tests
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Fig. 8 Role of LRP1 in CXCR3-A activation and function. a Calcium ﬂux assessed by FACS analysis in U87-CTRL and U87-CXCR3-A cells after treatment
with control SiRNA (Si CTRL) or LRP1 SiRNA (Si LRP1-1). b Calcium ﬂux in T98G cells, which express endogenous level of CXCR3-A. NS non-stimulated
condition, DMSO negative control, 20 s PS 20 s post stimulation, 3 min PS 3min post stimulation, a.u. arbitrary unit. ***P<0.001, **P<0.01, *P<0.05, NS
non-signiﬁcant. c Western blot for phosphorylated ERK1/2 in U87-CXCR3-A cell extract from Si LRP1-1 or RAP-treated cells after 60min of stimulation
with PS372424. Vinculin and total ERK used as loading controls. dMigration assays (n= 3) on U87-CTRL or U87-CXCR3-A cells performed after silencing
of LRP1 (left panels) or inhibition of LRP1 (RAP, right panels). ***P<0.001, NS non-signiﬁcant. e LRP1 (λ= 488 nm) and vimentin (λ= 547 nm)
immunostaining were performed at the interface between the CAM and the U87-CTRL or U87-CXCR3-A tumor. Nuclei were stained with DAPI (λ= 405
nm). Scale: 10 µm. All the results from three independent experiments were combined to calculate mean and SEM, and values were normalized to those
obtained for the control condition. Multiple comparisons were performed with one-way analysis of variance, followed by Bonferroni post hoc tests
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medium (NBM, Thermo Fisher Scientiﬁc) supplemented with 0.2% heparin and
0.02% basic ﬁbroblast growth factors. Adherent human embryonic kidney cell line
(HEK-293, ATCC), coronay artery smooth muscle cells (CaSMC, Lonza), and
glioma cell lines (U87 (ATCC), U118 (ATCC), 1321N1 (Sigma), NHATS&N-
HATSR) (kindly donated by Dr. K. Sasai, Hokkaido University, Sapporo)64 and
T98G (Sigma) were regularly tested for contamination and were all mycoplasma-
free. Cells were cultured in Dulbecco’s Modiﬁed Eagle’s medium (DMEM, Thermo
Fisher Scientiﬁc) supplemented with 10% fetal bovine serum (FBS), 5% antibiotics
(Penicillin and Streptavidin), and 5% L-glutamine. All cells were grown at 37 °C, 5%
CO2, and split at 70–90% of conﬂuence with 0.25% Trypsin. Potential mis-
sidentiﬁed cell lines including HEK-293 and U118 were used for the following
reasons: Hek-293 cells do not express CXCR3 (Fig. 1a) and LRP1 (Fig. 4b), and
were engineered with CXCR3-A expression vectors; U118 were only used for the
analysis of expression of CXCR3, but were not used in any other experiment. All
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cells used for phenotypic and functional studies have been further characterized
more in detail by cGH array (P3) and by cell authentiﬁcation using Promega
Powerplex21 Kit (Euroﬁns, GE) (cell lines). Cell transfection was performed using
Effecten kit (Qiagen) according to the manufacturer’s instruction. U87-CTRL
(U87 stably transfected with empty pCDNA3.1 vectors) and U87-CXCR3-A cells
(U87 stably transfected with pCDNA3.1+CXCR3-A vectors) were grown in the
presence of G418 antibiotics (500 μg/ml). HEK-CTRL (HEK-293 stably transfected
with empty pEGFPN2 vectors) and HEK-CXCR3-A cells (HEK-293 stably trans-
fected with pEGFPN2+CXCR3-A vectors) were grown in the presence of Zeocin
(200 µg/ml). A HA-tagged mini-LRP1 construct carrying only the ligand-binding
domain IV (HA-LRPIV) was generated as described33 and used to stably transfect
both HEK-CTRL and HEK-CXCR3-A. After transfection, these cells were grown in
the presence of Zeocin (200 µg/ml) and G418 (750 µg/ml).
For inhibition experiments, cells were pretreated: 1 h with SCH546738 at 2.2
nM, 15 min with Pitstop2 at 30 µM, or 24 h with RAP at 5 µM.
P3 xenograft spheroids were maintained in culture onto agar-layered ﬂasks and
then transplanted into randomly selected immunodeﬁcient RAGγ2C−/−. Male
RAGγ2C−/− mice (n= 10, 7–9-week-old) were housed and treated in the animal
facility of Bordeaux University (“Animalerie Mutualisée Bordeaux”). Power
calculation was not done in this case since these are qualitative data and each
animal is its own control (comparison of central and invasive areas for each
animal). All animal procedures have been done according to the institutional
guidelines and approved by the local ethics committee (agreement number: C-33-
522-2). Animals were killed and tumoral brains were cut into 10 μm cryosections
for immunostainings.
CAM assays. Fertilized chicken eggs (Gallus gallus) (less sentient model according
to 3R rule) were incubated at 37 °C and 65% humidiﬁed atmosphere and submitted
to a rotation of 25° every 4 h during 3 days. On day 3 of development, a window
was made in the eggshell and sealed with Durapore tape. On day 10, plastic rings
(made from Nunc Thermanox coverslips) were put on the CAM. Three millions of
U87-CTRL or U87-CXCR3-A cells were deposited as a thin layer on the surface of
the CAM, inside the plastic ring, after gentle laceration of the surface. On day 17,
the CAMs were ﬁxed in vivo with 4% paraformaldehyde for 30 min at room
temperature. The area containing the ring was cut out and included in optimal
cutting temperature compound (OCT) or directly frozen in liquid nitrogen, for
further analysis. For the ﬁrst condition, 40 eggs each were implanted with either
U87-CTRL cells or U87-CXCR3-A cells. Among those, 21 U87-CTRL eggs and 23
U87-CXCR3-A eggs survived, analyzed by biomicroscopy and further processed. 1/
3 of the CAM were included in OCT for histology and immunostaining and 2/3
were frozen for mRNA and protein extraction. For the second condition, 24 U87-
CXCR3-A CAMs were treated with SCH546738 and 10 U87-CXCR3-A CAM with
DMSO. Eggs for cell implantation or SCH546738 treatment were randomly
selected. Expecting that 75% of the U87-CXCR3-A eggs would have an invasive
phenotype, that 75% of the U87-CTRL eggs would have an angiogenic phenotype
and similarly that 75% of the untreated (DMSO) U87-CXCR3-A eggs would have
an invasive phenotype and that 75% of the treated U87-CXCR3-A eggs would have
an angiogenic phenotype, these group sizes correspond, respectively, to a 94% and
a 80% power for two sided tests comparing two binomial proportions with sig-
niﬁcance level 0.0565.
Glioblastoma patients. Patients with preoperative MR imaging studies suggesting
a presumptive diagnosis of GBM (deﬁned as intracerebral mass lesion with contrast
enhancement area at post gadolinium T1-weighted MR) were included in the study
Volumetric FLAIR and post gadolinium T1-weighted images of these patients were
obtained in the preoperative period and loaded into the neuronavigation plan
(Brainlab workstation) to be available during surgery for intraoperative tracking.
Informed written consent was obtained from all subjects (Department of Neuro-
surgery, Humanitas, Milano acoording to Humanitas ethical committee
regulations).
At surgery, various samples were collected at the peripheral region of the tumor
(inﬁltrative area deﬁned as FLAIR abnormalities around and distant from post
gadolinium T1 contrast enhancement ring) or at the tumor core (deﬁned as
contrast enhancement area at the tumor ring in post gadolinium T1-weighted
images). The site of collection was registered every time on the neuronavigation
system and data were stored and collected for subsequent analysis. Part of the
samples were immediatly frozen and stored in the tumor bank. Part of the samples
were sent for routine histological and molecular analysis (IDH1 mutation, MGMT
promoter methylation status, 1p/19q codeletion, ATRX expression). Only patients
with a histological diagnosis of GBM and IDH1 wt proﬁle were included.
Plasmon waveguide resonance. PWR measurements were performed in a
homemade instrument equiped with a He-Ne laser, with a ﬁxed wavelenght in the
visible region (λ= 632 nm; Melles Griot), a rotating table allowing the incident
angle to be changed by steps ≤ 1 mdeg (thus resolution being on that order;
Newport) and a photodiode detector (Hamamatsu) to measure the reﬂected light as
a function of the incident angle. The polarization angle of the incident beam is
placed at 45° allowing both p- and s-polarized spectra to be obtained within the
same angular scan. The sensor consisted in a BK-7 prism coated with silver and
silica (to support waveguide modes)29. All measurements were performed at 22 °C
in a temperature controlled room. More details about this technology can be found
in Harte et al.29 publication.
The protocol for adhesion of cell fragments on silica (glass slides or PWR
sensor) was adapted from reported work from Vogel and collaborators66. Brieﬂy,
the silica surface was washed with ethanol and cleaned and activated by plasma
cleaner for 2 min (Diener). The silica surfaces are then incubated with a solution of
polylysine (0.1 mg/ml) for 40 min following wash with PBS buffer. Cells grown to
< 50% conﬂuence are washed with PBS and covered with water to induce osmotic
swelling of the cells. Imediately, the glass coverslip of the sensor is placed directly
on top of cells. Pressure is applied for about 2 min on the glass slide or prism to
induce cell rupture and caption of cell fragments. After that they are removed
ripping off cell fragments containing specially the upper membrane. The glass slide
or sensor is washed with PBS to remove cell debris and kept with buffer to prevent
drying and loss of membrane protein activity. PWR measurements are performed
right away. The PWR cell sample (a teﬂon block with a volume capacity of 250 μl)
is placed in contact with the prism and ﬁlled with PBS. After cell fragment
deposition, there are positive shifts in the resonance minimum position that are
correlated with the total mass gain occurring. We have observed spectral shifts that
correlate with those observed for the deposition of lipid model membrane. In the
case presented here, there are areas of the sensor covered with cell membranes and
others uncovered (as observed by confocal microscopy on ﬂuorescently labeled
cells (Supplementary Fig. 2A), the PWR signal takes into account both covered and
uncovered areas as the laser spot makes about 0.5 mm in diameter. At same time,
covered areas include both lipids and proteins, so possess a higher mass than that
of a pure lipid membrane. Following stabilization of the signal (no changes in the
resonance minimum position with time), the ligand is added in a incremental
fashion to this chamber and specral shifts followed with time. The ligand mass itself
is small and cannot account for the observed spectral changes that are attributed to
the changes in receptor conformation following ligand binding (formation of the
receptor/ligand R/L complex). Ligand afﬁnity to the receptor present in the cell
membrane fragments is calculated by ploting the shifts in the resonance minimum
position (corresponding to R/L complex) as a function of ligand concentration
(free ligand, L) and ﬁtting using an hyperbolic function that describes ligand
binding to a protein (single site) (Graph Pad Prism).
Protein structure modeling and molecular docking. There are lacking of
structures of CXCR3-A and LRP1-CR26 and CR27. We used protein fold recog-
nition server, Phyre267, to build the modeling structures of CXCR3 and CR26,
CR27, adopting CXCR4 (PDB code 3ODU) and LRP1 CR17 (PDB code 2KNY) as
templates. The molecular docking between CXCR3-A and CR26 (and CR27) was
predicted by using HADDOCK2.2 software36, 37 that implements CNS calcula-
tion68. We followed the protein–protein docking protocol and used the negatively
charged residues distributed on CXCR3 extracellular surface and the positively
charged residues on CR26 (/CR27) N-terminal half to be the ambiguous interaction
restraints. The ﬁnal complexes were evaluated by HADDOCK score and structure
clusters. The structures occurred in the most favorable cluster and with smaller
Fig. 9 CXCR3 and LRP1 expression in glioblastoma samples from patients. a HE staining was performed in the experimental mouse intracranial P3 GBM
model that recapitulates the regional heterogeneity of gliomas. (1) healthy brain, (2) angiogenic part, and (3) invasive part. b Immunoﬂuorescence with
anti-vimentin (sc-6260 clone V9, Santa Cruz) (λ= 547 nm) and anti-LRP1 (antibody 2703-1 for LRP1β, Epitomics) (λ= 488 nm) antibodies on tissue from
healthy mouse brain, angiogenic, or invasive part of the P3 GBM tumor. Scale: 5 µm. c Graph depicts the quantiﬁcation of LRP1 expression in angiogenic and
invasive areas (n= 30). ***P<0.001. d MRI image from a representative glioblastoma (GBM) patient. Samples were taken intraoperatively with the aid of
neuronavigation from the tumor angiogenic core (contrast enhancement ring) and the inﬁltrative area (T1 hypointense abnormality). e
Immunoﬂuorescence with anti-CXCR3 (antibody 2ar1, Abcam) and anti-LRP1 antibodies (antibody 2703-1 for LRP1β, Epitomics) (λ= 488 nm) on tissue
samples from either the angiogenic or invasive part of the tumor. Membrane and/or perinuclear localization of CXCR3 and LRP1 were observed at a ×630
magniﬁcation with phase contrast brightﬁeld under a confocal laser scanning microscope (Nikon Eclipse ti). Scale: 5 μm. Graphs (protein intensity, n= 30,
and CXCR3 localization, n> 300) depict the quantiﬁcation from three different patients. NS non-signiﬁcant. ***P<0.001. Statistical comparison between
two groups was performed using the Mann–Whitney U-test. Multiple comparisons were performed with one-way analysis of variance, followed by
Bonferroni post hoc tests
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HADDOCK score were considered to be the most reliable complexes. Meanwhile,
because of domain repeats in LRPIV, we selected the CR structures with the N- and
C-terminal ends free access for conjugating the previous and next Crs.
For modeling of the CXCR3-A/CXCL10 complex, we used the complex
structure of CXCR4 and vMIP-II (pdb code 4RWS)35 as template. The CXCR4
coordinate was replaced by CXCR3-A and the vMIP-II coordinate by CXCL10. For
modeling of the CXCR3-A/PS372424 complex, the binding site of the agonist was
derived from the residues identiﬁed in the modeling CXCR3–Cp#1 complex69.
Western blot and immunoprecipitation analysis. Cells were washed twice with
PBS and dissolved in lysis buffer (10 mM Tris-Hcl, pH 7.4, 150 mM NaCl, 0.5%
NP-40, 1% TritonX-100, 1 mM EDTA supplemented with protease and phos-
phatase inhibitors cocktails (Roche). Protein concentration was quantiﬁed by
Bradford assay (Euromedex). Cell lysates were resuspended in Laemmli buffer
(62.5 mM Tris pH 6.8, 10% glycerol, 2.5% SDS, 2.5% β-mercaptoethanol), boiled
for 5 min and resolved by SDS–PAGE. For immunoprecipitation, 500 µg of pre-
cleared cell lysate was incubated with 5 μg/ml anti-LRP1 (8G1, ref: ab20384,
Abcam), 5 μg/ml anti-CXCR3 antibodies (1C6, ref: ab125255, Abcam), or 5 µg/ml
of control IgG (rabbit IgG ref: X0903, DAKO; Mouse IgG ref: MABC002, Milli-
pore) overnight at 4 °C, and then with protein G-Sepharose (Amersham) for 2 h at
4 °C. For both immunoprecipitations, the immunocomplexes were then washed
three times in lysis buffer and twice in PBS. For western blot, 50 µg of protein cell
lysate was used for each conditions. All samples were boiled in 4× sample buffer,
subjected to electrophoresis and transferred. Proteins were electroblotted onto a
polyvinylidene diﬂuoride (PVDF) membrane (ref: 10344661, Fisher Scientiﬁc).
Membranes were incubated with blocking buffer (ref: 927-40003, EuroBio) for 1 h,
probed overnight at 4 °C with the primary antibodies of interest (Anti-LRP1 (ref:
2703-1, dilution: 1/5000), anti-LRP1 (ref: D2642, dilution: 1/1000), anti-CXCR3
(ref: ab77907, dilution: 1/500), anti-CXCR4 (ref: ab72100, dilution: 1/200), anti-
CXCR7 (ref: ab124824, dilution: 1/100) PathScan Multiplex western Cocktail I (ref:
5301S, dilution: 1/250), total p42/p44 MAPK (ref: 9102, dilution: 1/1000), anti-
vinculin (ref: V9131, dilution: 1/2000), anti-GFP (ref: sc-9996, dilution: 1/2000),
anti-clathrin from Vesicle Trafﬁcking Antibody Sampler Kit (ref: 9765, dilution:
1/1000), anti-caveolin1 from Vesicle Trafﬁcking Antibody Sampler Kit (ref: 9765,
dilution: 1/1000)), followed by detection using secondary antibodies coupled to
Fluoroprobes (goat anti-rabbit IR Dye 680CW, ref: 926-68021; goat anti-rabbit IR
Dye 800CW, ref: 926-32211; goat anti-mouse IR Dye 680CW, 926-68020; goat
anti-mouse IR Dye 800CW, ref: 926-32210 or goat anti rat IR Dye 800CW, ref:
926-32219, dilution: 1/5000, Li-Cor Biosciences) and Odyssey infrared imaging
system (Li-Cor Biosciences, Nebraska, US). Densitometry analysis was performed
using Image Studio Lite 4.0 software. Uncropped immunoblots are depicted in
Supplementary Figs. 7–11.
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Indirect immunoﬂuorescence staining. Cells were seeded on glass coverslips and
ﬁxed 10 min with 4% paraformaldehyde at room temperature. Cells were per-
meabilized 10 min with 0.1% TritonX-100, washed with PBS and incubated for 1 h
with blocking buffer (PBS containing 2% FBS and 1% BSA) at room temperature.
Cells were incubated with primary antibodies diluted in blocking buffer overnight
at 4 °C (anti-CXCR3 (ref: ab64714, dilution: 1/300), anti-LRP1 (ref: 2703-1, dilu-
tion: 1/500), anti-clathrin from Vesicle Trafﬁcking Antibody Sampler Kit (ref:
9765, dilution: 1/50), anti-caveolin1 from Vesicle Trafﬁcking Antibody Sampler Kit
(ref: 9765, dilution: 1/400), anti-EEA1 Vesicle Trafﬁcking Antibody Sampler Kit
(ref: 9765, dilution: 1/200), anti-GOPC from Vesicle Trafﬁcking Antibody Sampler
Kit (ref: 9765, dilution: 1/100), anti-syntaxin6 from Vesicle Trafﬁcking Antibody
Sampler Kit (ref: 9765, dilution: 1/100), anti-Rab5 from Endosomal Marker
Antibody Sampler Kit (ref: 12666, dilution: 1/200), anti- β-Arrestin (ref: 610550,
dilution: 1/200)), washed with PBS, and incubated with secondary antibodies
diluted in blocking buffer (Interchim, FluoProbes 488H goat anti-mouse IgG (H
+L) (A11001), FluoProbes 647H donkey anti-mouse IgG (H+L) (FP-SC4110),
FluoProbes 488H donkey anti-rabbit IgG (H+L) (FP-SA5110) or FluoProbes 647H
goat anti-rabbit IgG (A-21246), dilution: 1/500). Dapi was used as counterstained
agent to label nuclei (Fisher Scientiﬁc, ref: 10374168, dilution: 1/2000). Coverslips
were mounted using Prolong Gold antifade reagent (Fisher Scientiﬁc, ref:
11559306). For STED microscopy staining, secondary antibody (STAR 580 and
ATTO 647N) were a kind gift from the Bordeaux Imaging Center (BIC).
Histological and immunoﬂuorescence analyses. CAM tissues embedded in OCT
were cut in frozen sections of 10 µm using the cryostat LEICA CM1900. For
histological analyses, frozen sections were stained with haemotoxylin and eosin.
For immunohistoﬂuorescence analyzes, frozen sections were incubated with pri-
mary antibodies anti-vimentin (ref: sc-6260 clone V9, dilution: 1/400) anti-CXCR3
(ref: ab64714, dilution: 1/300), and anti-LRP1 (ref: 2703-1, dilution: 1/500).
Fluorescent secondary antibodies (the same as described in indirect immuno-
ﬂuorescence staining) were used for labeling and DAPI was used to stain nuclei
(Fisher Scientiﬁc, ref: 10374168, dilution: 1/2000).
Confocal and STED microscopy. Confocal images were acquired with a Nikon
Eclipse Ti inverted laser scanning ﬂuorescence microscope equipped with acqui-
sition software (NIS-Element, NIS) and 63× oil immersion objective (numerical
aperture (NA), 1.4). Triple or quadruple imaging were obtained using selective
laser excitation (405, 488, 547, or 647 nm). Each channel was imaged sequentially
before merging. Z-stack images were taken at sequential 1 µm depth slices and 3D
representation were performed on NIS Element software. STED images were
acquired in the BIC institute with a Leica SP8-STED microscope equipped with
LAS-AF software and with 100× oil immersion objective. The depletion laser was
used at 775 nm. Plot proﬁle analysis was performed on ImageJ software.
Calcium measurement. Intracellular calcium concentration was measured using
Calcium Assay Kit (ref: 640176, BD Pharmingen) according to the manufacturer’s
procedure. In brief, cells were placed in suspension and ×1 Dye loading solution
was added for 20 min at 37 °C. Calcium concentration was then recorded for 5 min
on the AccuriC6 ﬂow cytometer. CXCR3 agonist stimulation was performed after
2 min of recording and intracellular calcium increase was visualized. Calcium
concentration after stimulation was normalized by calcium concentration before
stimulation. Cells without ×1 dye loading solution were used as a negative control
in order to quantify the background level.
Proximity ligation assay. PLA was performed according to the manufacturer’s
procedure using the Duolink In Situ Orange Starter Kit Mouse/Rabbit (ref:
DUO92102, Sigma). The primary antibodies used were for CXCR3 mouse antibody
2ar1 (ref: ab64714, dilution: 1/300) and for LRP1 rabbit antibody (ref: 2703-1,
dilution: 1/500). Before the PLA procedure with secondary antibodies, the protocol
described for the indirect immunoﬂuorescence staining was used.
Immunogold and electron microscopic localization. Subconﬂuent U87-CXCR3-
A cells stimulated 60 min with CXCR3 agonist were ﬁxed in a mixture of 2%
paraformaldehyde and 0.1% glutaraldéhyde in 0.1 M sodium phosphate buffer, pH
7.4 for 1 h and kept in 0.1 M sodium phosphate buffer until further processing. Cell
samples were embedded in 10% gelatin, which was solidiﬁed on ice. Blocks with
cells were immersed in 2.3 M sucrose in phosphate buffer at 4 °C, and ultra-thin
cryosections were single or double immunolabeled with 6- and 15-nm protein A-
conjugated colloidal gold probes. The rabbit antibodies used were against syntaxin
6 (6 nm, ref: 2869 Cell Signaling, dilution: 1/10) and the mouse antibodies used
were agiants CXCR3 (15 nm, ref: 2ar1 ab64714, dilution: 1/300). The labeled sec-
tions were contrasted with uranyl acetate and embedded in methyl cellulose.
Statistical analysis. Statistical analysis was performed using the GraphPad Prism
5 software and NIS-Element AR 64-Bit software for Pearson’s analyses. For the
statistical tests used, see ﬁgure legends.
Data availability. All data are available within the Article and Supplementary Files,
or available from the authors upon request.
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